Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Correct is an understatement compared to how accurate this time ORCA may be. This Otiko seems to be stalling over something that went wrong and he is doubling down to get it straight or something. I knew something went wrong with this man...
This, of course was not a Friend of my Friend who told me this now, it is only my speculation. I just want to be clear to some flamboyant fans I got in here
VIVA VDRM, LOOKING TO WALK AWAY WITH MY PRINCIPAL ONLY.... That is all I ask, not profit, NADA. Just my principal
You may be correct on all points. :)
The old website was a lot better IMO. Not even sure what their business angle is now. Did they move into pet health for veterinarians? Vitastem is being used to treat horses, cows, sheep, rabbits, and chickens too?
Funny how this receives a clown and poop emoji when this is 💯 correct.
We will know something sooner than later.
We know things are happening All good
Yes, you are correct, the site is updated with new perks. Same site but with new features. OTIKO is an enigma, nobody knows what will come next but right now, something stench and smelly going on. No proof of nothing he promised will come to fruition. Until fillings demonstrate otherwise, we’re in limbo.
This was not said by the friend of my friend by the way. Just clarifying to my flamboyant fans in here. My speculation only
It does seem to be a good looking website..has anyone personally ordered from it recently?
They added a lot to the site Now treating animals.
Yes the newly up dated site. GO VDRM
Anyone checked out the new website?
https://getvitastem.com/
Hasn't "seemed right" for years......
CBIA just posted its attorney letter and the letter is dated as today. This means OTIKO is not really delayed on fillings, he has not submitted anything yet. OTCM is not in delays. I have noticed other companies publishing in twitter their submission WAY after OTIKO and somehow their fillings are OUT!!! CBIA is a proof of such!!! It was not a friend of my friend who told me such, it is my own speculation... This is for the fans I got in here, lol
Otiko smells now, something is not right
ORCA posted such 4 hrs. ago.
THE BID GOT HIT,.RIGHT AFTER MY POST.LMAOOOOOO.HIT THE REST.GTSM.COME DOWN BRO AND HIT THE REST.A .002 DOES NOT MAKE MUCH DIFFERENCE.
Can someone translate this shit please?
THE 40 MILLION HAS BEEN HITTING THE MARKET.VIA GTSM.I AM HOPING HE WILL DUMP ON THE BIG BID SOON,SO WE CAN LOAD UP SOME .009S.AROUND 10 MILLION SHARES.I WANT TO GET A GOOD HOLD ON IT.SO I CAN SHAKE OUT THE 40 MILLION IN THE .006 AND .007.GTSM.BECAREFUL NO TO DUMP SHARES ON MY LAP.LMAOOOOOOO.
sluggercjb No one can argue that.
Exactly what I have been saying.
guess we are tired of hearing the check is in the mail couple of years ago with that kind of news we would be off and running well past 04 and .07 now we need to see a $$$$ check $$$$$ clear the Bank
I don’t see that Tweet. Did you make it up? Are you the one who hacked their account and is posting BS posts???
AGREE.IF IT IS TRUE.WE ARE BETTING IT IS. THUS WE ARE HOLDING SHARES.
Zero traction in the USA but hundeds of thousands of units in the Middle East coming. Seems legit
I have looked all over X And can't find anything on new updates
I’m still waiting on the 12 mill/yr from Japan.
IF and I mean IF, this is true
---------------
Feb 1
$VDRM Update: The company has received licensing payments totaling $1.2M and will be updated into our financials accordingly. More updates to follow.
---------------
It's nothing more than Peter paying Paul to make the books look good. Because he(the good doctor), has ownership in the leasing company.
IMHO
Yeah. And 600k was sitting in escrow
indyterp can you post that link please?
Lol!!
Foreign contracts/distribution etc were supposively happening each year for the last several years. There is a reason no specifics are ever given 😢 Red flags for any ticker.....
THE TWO LAST UPDATES.THE ONE SAYS.THEY ALREADY RECEIVED $1,2 MILLION.AND WILL SHOW ON THE FINANCIALS.THIS IS HUGE MONEY IF TRUE.AND IT HAS TO BE TRUE.BECAUSE THEY GOT IT ALREADY.MORE UPDATES TO FOLLOW.
ViaDerma
@viaderma
·
Feb 1
$VDRM Update: The company has received licensing payments totaling $1.2M and will be updated into our financials accordingly. More updates to follow.
ViaDerma
@viaderma
·
Jan 31
$VDRM Update: We received very positive feedback and have successfully completed the stability requirements for the Vitastem Ultra bacitracin formula. The company is on track to begin shipping
@vitastem
overseas in March.
I GUESS THAT EXPLAINS THE HUGE BIDDER.HMMM.
March coming soon. I want news of check CLEARED !!!
Huge VDRM news posted on Twitter. Vitastem testing completed, and company will be ready to start foreign distribution in March.
Someone said they got a e-mail from IR
Unless they aren't willing to lie🤷
it is disturbing to think the company gave all of those shares to the supposed IR person and nothing is getting done in the way of investor relations! no press releases updating and expanding on the tweets put out there.
Are you going to start selling today? Or why Should that 4 mil go through? Thanks
Thurs. we should see that 4 mill go thru
Still crying here? Poor thing…. lol
Now a nicer bid of 4,261,000
A nice bid of 3.761 million at .01. been a long time since we have had a good run, years !!
OTIKO=LYING SCAMBAG.THE ONLY WAY TO MAKE MONEY ON THIS SHARE SELLING SCAM,IS FLIPPING IT,AND EVEN THAT YOU HAVE TO BE A PRO.OR LOSE YOUR SHIRT.
And if you buy in at .0085 he'll have found the towel he threw. We know already. :)
I can’t knock his hustle, Dr has made a killing off of this.
Have to say if I was in his shoes I wouldn’t be able to sleep at night. All good
Followers
|
617
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74429
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |